Shen Mengya, Xiao Yang, Ma Lijing, Wang Jun
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2020 Dec;34(12):1145-1148. doi: 10.13201/j.issn.2096-7993.2020.12.022.
Recurrent respiratory papillomatosis （RRP） is a benign tumor of the respiratory tract caused by human papillomavirus （HPV） infection. At present, there is no cure for this disease, and mainly depends on surgical resection to relieve symptoms but cannot prevent recurrence. Multiple surgeries will bring heavy mental and economic burdens to patients and their families. Therefore, researchers are constantly seeking new treatments to reduce the number of operations and prevent recurrence. Hence, research on adjuvant therapy drugs has also been widely carried out, including bevacizumab, cidofovir, HPV vaccine, and Chinese medicine as an adjuvant drug according some reports. This article reviews the adjuvant treatment of RRP in recent years.
复发性呼吸道乳头状瘤病（RRP）是一种由人乳头瘤病毒（HPV）感染引起的呼吸道良性肿瘤。目前，这种疾病无法治愈，主要依靠手术切除来缓解症状，但无法预防复发。多次手术会给患者及其家庭带来沉重的精神和经济负担。因此，研究人员一直在寻找新的治疗方法以减少手术次数并预防复发。于是，针对辅助治疗药物的研究也广泛开展，据一些报道，包括贝伐单抗、西多福韦、HPV疫苗以及中药作为辅助药物。本文综述了近年来RRP的辅助治疗情况。
